Investor Presentaiton
Growth levers for the future - US business
☐
Revenue FY21
50+ products in various
therapy area segments
Positioned in the niche soft
gel category
☐
Strong distribution
Channel marketing for both
OTC and Rx products
23 ANDAs filed till date
Organic Growth
Expanding presence in other
North American regions
Increase in ANDA filings for
soft gel dosages
Partnership with leading
retailers
Exploiting untapped
potential of drugs going off
patent
New Products in Pipeline
25 products identified with a
focus on soft gels and OTC
products
15 products in R&D
☐
Inorganic Growth
Planning to acquire ANDAS
to cut short development
time
■ Increasing capacity in India
and US facility to meet
future requirements
Revenue FY25
■ To achieve a sustainable
growth and profitability
©2021 - Marksans Pharma Limited, All Rights Reserved.
45
25View entire presentation